1	Hybrid adaptive immunity to SARS-CoV-2 protects against breakthrough infection after
2	COVID-19 vaccination in ALSPAC participants
3	
4	Holly E. Baum ^{>1,2} , Marianna Santopaolo ^{>1} , Ore Francis ^{1,3} , Emily Milowdowski ³ , Katrina
5	Entwistle ³ , Elizabeth Oliver ^{1,2} , Benjamin Hitchings ^{1,2} , Divya Diamond ¹ , Amy C. Thomas ⁴ , Ruth
6	E. Mitchell ⁴ , Milla Kibble ^{4,5,6} , Kapil Gupta ⁷ , Natalie Di Bartolo ⁷ , Paul Klenerman ⁸ , Anthony
7	Brown ⁹ , Begonia Morales-Aza ^{1,2} , Jennifer Oliver ^{2,4} , Imre Berger ⁷ , Ash M. Toye ⁷ , Adam Finn
8	^{1,2,4,10} , Anu Goenka ^{1,2,4,10} , Andrew D. Davidson ¹ , Susan Ring ^{4, 11} , Lynn Molloy ⁴ , Melanie
9	Lewcock ⁴ , Kate Northstone ⁴ , Firona Roth ⁴ , Nicholas J. Timpson ^{4, 11} , Linda Wooldridge ³ , Alice
10	Halliday ^{^1,2} , Laura Rivino ^{*^1}
11	
12	¹ School of Cellular and Molecular Medicine, Faculty of Health and Life Sciences, University of
13	Bristol, Bristol, UK
14	² Bristol Vaccine Centre, University of Bristol, Bristol, UK
15	³ Bristol Veterinary School, Faculty of Health and Life Sciences, University of Bristol, Bristol, UK
16	⁴ Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
17	⁵ Department of Applied Mathematics & Theoretical Physics, University of Cambridge,
18	Cambridge, UK
19	⁶ Department of Twin Research and Genetic Epidemiology, King's College London, London, UK
20	⁷ School of Biochemistry, Faculty of Health and Life Sciences, University of Bristol, Bristol, UK
21	⁸ Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, Oxford,
22	UK
23	⁹ Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK
24	¹⁰ Department of Paediatric Immunology and Infectious Diseases, Bristol Royal Hospital for
25	Children, Bristol, UK
26	¹¹ MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK
27	
28	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. FIRST AUTHORS CONTRIBUTED EQUALLY

29 ^ Senior authors contributed equally

- 30 * Corresponding author / Lead contact
- 31

32 Correspondence: Dr Laura Rivino (Laura.Rivino@bristol.ac.uk)

33

34 SUMMARY

Immunological memory to vaccination and viral infection involves coordinated action of B and T-35 cells, thus integrated analysis of these two components is critical for understanding their 36 contributions to protection against breakthrough infections (BI). We investigated cellular and 37 humoral immune responses to SARS-CoV-2 infection and/or COVID-19 vaccination in 38 participants from the Avon Longitudinal Study of Parents and Children (ALSPAC). The magnitude 39 of antibody and T-cell responses following the second vaccine dose was associated with 40 protection against BI in participants with a history of SARS-CoV-2 infection (cases), but not in 41 infection-naïve controls. Youden's index thresholds for protection against BI were calculated for 42 all immune measures. Anti-Spike IgG (>666.4 BAU/mL) and anti-Nucleocapsid pan Ig (>0.1332 43 BAU/mL) thresholds combined were 100% specific and 83.3% sensitive for cases without BI over 44 8-months follow-up. Collectively these results point to the superior protective effect of hybrid 45 immunity and have implications for the design of next-generation COVID-19 vaccines. 46

47

48 KEYWORDS

ALSPAC, SARS-CoV-2, COVID-19, adaptive immunity, T-cells, antibodies, infection,
 vaccination, hybrid immunity, breakthrough infection

51

52 **INTRODUCTION**

The COVID-19 pandemic caused substantive medical and socioeconomic burdens that continue
 to affect the global population¹⁻⁴. Infection with severe acute respiratory syndrome coronavirus 2

(SARS-CoV-2) presents as a broad spectrum of clinical manifestations from asymptomatic or mild infections, through to severe illness, and associated mortality^{5,6}. The rapid deployment of COVID-19 vaccines proved instrumental in reducing SARS-CoV-2 infections and subsequent hospitalisations and deaths, however vaccine effectiveness wanes over time^{7–9}. Breakthrough infections (BIs) are well documented and are influenced not only by waning immunity, but also the evolution of novel viral variants^{10–13}.

61

A broad repertoire of antibody and cellular responses are elicited by SARS-CoV-2 infection^{14–16} 62 and COVID-19 vaccination^{17–19}. Evidence for anti-Spike (S) IgG and neutralizing antibody titres 63 as correlates of protection (COPs) against SARS-CoV-2 infection and severe disease have been 64 demonstrated in COVID-19 vaccine trials^{20,21}, and studies of BIs^{12,13}. Additionally, both systemic 65 and mucosal IgA have been implicated in protection against infection²²⁻²⁴. SARS-CoV-2-specific 66 T-cell responses are more durable than antibodies²⁵, and may therefore be important for 67 protection longer-term, and against novel variants which can evade antibody-mediated 68 69 immunity^{26,27}. Furthermore, cross-reactive T-cells can enhance infection- and vaccine-mediated responses²⁸ and induce abortive infections in highly exposed individuals²⁹. 70

71

Anti-viral immune memory responses are determined by the coordinated action of antibodies and 72 T-cells targeting the virus, and an integrated analysis of these two components is therefore critical 73 74 for understanding their contributions to protection. In this study we investigate the cellular and 75 humoral responses to SARS-CoV-2 after infection and/or vaccination in participants from the Avon Longitudinal Study of Parents and Children (ALSPAC). We further address the role of 76 antibodies and T-cells in providing protection against BI in participants with hybrid immunity, 77 78 induced by a combination of SARS-CoV-2 infection and COVID-19 vaccination, as compared to those with vaccine-induced immunity alone. 79

- 80
- 81

82 **RESULTS**

83 Study design and recruitment

This study was open to ALSPAC participants of the G0 (48-70 years) and G1 (29-30 years) 84 85 generations. 377 participants enrolled, and attended clinics in December 2020, March 2021, and June 2021 (Figure 1). Study participants were 59.2% female, 97.8% white, and 58.5% G1 86 generation (Table S1). Participants were selected from a cohort of 4819 individuals who had a 87 valid SARS-CoV-2 antibody lateral flow test (LFT) result in October 2020. LFT anti-S IgG 88 positivity rates were 3.1% and 5.8% in the G0 and G1 generations respectively (Figure 1). These 89 results were used as an initial screen to identify participants with and without a likely history of 90 SARS-CoV-2 infection for inclusion in this study³⁰. 91

92

93 To validate the LFT results, serum samples from clinic 1 were screened for SARS-CoV-2-specific 94 anti-S and anti-Nucleocapsid (N) antibodies using in-house ELISAs. Participants were defined as 'cases' if they had a previous PCR-confirmed SARS-CoV-2 infection and/or were positive on 95 the anti-N or anti-Spike ELISAs (Figure 2A). The remaining seronegative individuals with no 96 97 history of COVID-19 are herein referred to as 'controls'. Clinic 1 samples were taken prior to participants being vaccinated as part of the UK COVID-19 vaccination programme. Of those who 98 provided information on their vaccination status, 64.0% had received at least one dose by clinic 99 2, rising to 97.0% by clinic 3 (Figure 1). Data was therefore analysed relative to the number of 100 101 COVID-19 vaccinations received (Figure S1), rather than chronologically by clinic, as this was 102 deemed to be the dominant variable influencing immune responses.

103

104 Antibody responses to COVID-19 vaccination

At baseline, anti-S and anti-N pan Ig levels were higher in cases compared to controls (P≤0.0001;
Figure 2A). A vaccine-induced increase in anti-S pan Ig was observed in both groups. Following
the second dose, all participants had anti-S pan Ig levels above the assay positivity threshold.
However, the case group retained their baseline advantage with higher median titres. Rates of
new SARS-CoV-2 infections between clinics 1-3 were low, with four individuals in the control

group reporting a positive PCR test. Consistent with this observation, a small increase in median anti-N pan Ig was observed after the first dose (P=0.0471), which plateaued after dose 2 (Figure 2A). This was predominantly driven by ≥2-fold increases in anti-N pan Ig levels in a small minority of participants (3/95; Figure S2). Anti-N pan Ig levels in the case group remained stable throughout.

115

Anti-S IgG in serum and saliva showed similar kinetics to serum anti-S pan Ig responses. Postvaccination anti-S IgG levels in the two sample types were very strongly correlated after the first (r_s =0.858, P≤0.0001) and second (r_s =0.809, P≤0.0001) doses (Figure 2C). Serum pseudoneutralising antibody titres in the case group increased in response to the first vaccination, then remained stable following the second dose (Figure 2B). A strong positive correlation between anti-S IgG and pseudoneutralising antibody titre was observed following each dose (r_s =0.784, P≤0.0001 / r_s =0.656, P≤0.0001; Figure S3).

123

Pre-vaccination anti-S IgA in serum and saliva was higher in cases than controls (Figure 2D). Serum anti-S IgA increased in both groups after the first dose, whilst median salivary anti-S IgA levels were not boosted by vaccination. There was therefore only a weak correlation between the two measures post-vaccination (r_s =0.355, P≤0.0001 / r_s =0.246, P=0.0045). Recipients of mRNA vaccines had higher median serum anti-S IgG and IgA levels than recipients of the adenoviral vector based ChAdOx1 (Figure S4).

130

131 **T-cell responses to COVID-19 vaccination**

T-cell responses targeting SARS-CoV-2 S1/S2, N, Membrane (M), Envelope (E), non-structural proteins (NSP3-16) and accessory proteins (ORF3, ORF6, ORF7 and ORF8) were measured by IFN- γ ELISpot (Figure S5A/B). Baseline S-specific IFN- γ responses were lower in controls compared to cases (P≤0.0001; Figure 2E). In both groups, S-specific T-cells increased after the first vaccination and then remained stable. In the case group, T-cell responses to N, M and NSP3B were not boosted by vaccination while those to NSP 1+2 increased after vaccination. In

contrast, increased T-cell responses to M (P≤0.0001), N (P=0.0175), and NSP3B (P=0.0091)
were observed in control participants after dose 2 compared to baseline (Figure 2E). T-cell
responses to NSP3-16, ORF3, ORF7 and ORF8, remained stable following vaccination (Figure S5A/B).

142

143 Magnitude and quality of T-cell responses to SARS-CoV-2 infection

The magnitude and functional phenotype of the CD4⁺ and CD8⁺ T-cell response targeting S, N, 144 M and NSP3B proteins were analysed in cases, prior to vaccination. Production of IFN-y, TNF-145 α, MIP1β, IL-2 and degranulation (CD107a) by SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells was 146 measured by ICS. A representative gating strategy is shown in Figure S6. Responses were 147 comprised of monofunctional and polyfunctional T-cells producing 1 or >1 effector functions 148 149 respectively, with monofunctional T-cells dominating both the CD4⁺ and CD8⁺ T-cell response 150 (Figure 3: see Table S2 for statistical comparisons). Monofunctional SARS-CoV-2-specific CD4+ T-cells produced mainly TNF-α (S1=59.03%, S2=28.45%, M=25.7%, N=41.35%, 151 NSP3B=27.35%) IFN-y (S1=23.59%, S2=16.75%, M=35.39%, 152 and N=34.55%, 153 NSP3B=48.34%). The frequencies of CD4⁺ T-cells producing each cytokine were comparable across proteins (Figure S7A). In contrast, CD107a was expressed at higher levels by CD4⁺ T-154 cells targeting M (34.26%), compared to S1 (5.25%), S2 (5.23%), and N proteins (9.42%). 155 Polyfunctional CD4⁺ T-cells were mainly IFN- γ^+ /TNF- α^+ , IL-2⁺/TNF- α^+ and IFN- γ^+ /IL-2⁺/TNF- α^+ 156 157 (Figure 3A).

158

Similarly to CD4⁺ T-cells, cytokine production by CD8⁺ T-cells targeting the different SARS-CoV-2 proteins was comparable while CD107a was expressed by a larger proportion of CD8⁺ T-cells specific for M compared to other proteins (M=31.7%, S1=1.63%, S2=4.91%, N=3.52%, NSP3B=4.27%) (Figure S7B). Polyfunctional CD8⁺ T-cells were mainly double or triple-cytokine producing, including IFN- γ^+ /TNF- α^+ , CD107a⁺/TNF- α^+ , MIP1 β^+ /IFN- α^+ , MIP1 β^+ /IFN- γ^+ and MIP1 β^+ /IFN- γ^+ /TNF- α^+ . NSP3B-specific CD8⁺ T-cells displayed higher polyfunctionality (14.8%) compared to those targeting S (S1=10.4%, S2=5.29%) or (N=5.33%) (Figure 3B; Figure S8A/B).

166

Association between post-vaccination immune responses and protection against SARS CoV-2 BI

We next investigated the relationship between the magnitude of antibody and T-cell responses 169 after the second vaccination, and protection against SARS-CoV-2 BI. The case and control 170 groups were subdivided based on self-reported guestionnaire data detailing whether the 171 participant had a PCR/LFT-confirmed SARS-CoV-2 infection in the 8-months following the 172 sample collection period (July 2021 - March 2022; Figure 1). For this analysis, the case group 173 174 was updated to include two individuals who had PCR-confirmed SARS-CoV-2 infections between clinics 1-3. BI rates were higher in the control group (42.4%) compared to the cases (30.8%). Of 175 the individuals who reported BIs, the median time since receiving a second vaccination, and the 176 177 proportion who received a third vaccination prior to infection, were comparable between cases and controls (Table S3). Self-reported BIs were consistent with increased rates of LFT anti-N IgG 178 positivity detected in the wider ALSPAC cohort in the period from May 2021 (G1=14.8%; 179 G0=9.8%) to May 2022 (G1=67.1%; G0=50.3%; Figure 1). 180

181

In participants without a history of COVID-19, there was no strong evidence of differences 182 between those who went on to experience a BI, compared to those who didn't, with respect to 183 the magnitude of immune variables measured (Figure S9A; Figure 4A). Conversely, previously 184 185 infected participants showed evidence of clustering by subsequent infection status (Figure 4B). 186 Higher levels of anti-S IgG in serum and saliva, pseudoneutralising antibody, and anti-S IgA in serum as well as S1-specific T-cell responses were observed in those with no reported BI (Figure 187 188 S9B). Similarly, high anti-N Pan Ig titres were associated with a decreased likelihood of re-189 infection. The lack of vaccine-induced salivary IgA in this cohort was reflected in the poor 190 performance of this measure as a discriminator of future infection susceptibility.

191

192 To compare the effectiveness of individual markers for discriminating between cases who did or 193 didn't go on to be re-infected, ROC curves were plotted, and thresholds calculated using the

Youden's Index method to balance sensitivity and specificity (Figure S10). Anti-S IgG ≥666.4 194 195 BAU/mL in serum (SP=87.5%), or 0.547 BAU/mL in saliva (SP=75.0%), provided 94.4% 196 sensitivity for identifying participants who didn't report BIs (Figure 4). Specificity was improved to 197 100.0% by combining serum or saliva S-specific IgG, and N-specific pan Ig, thresholds (SP=100%, SE=83.3%). Combining S-specific serum IgG with IgA in serum or saliva, or with T-198 cell responses, did not improve discrimination. Pseudoneutralising antibody ≥6165 units provided 199 a highly specific threshold (SP=100%) for identification of protected individuals, albeit with lower 200 201 sensitivity (SE=61.1%) than the S-specific IgG threshold (SE=94.4%).

202

The magnitude of T-cell responses to the S1 pool (SP=87.5%, SE=72.2%) provided a more specific and sensitive marker of infection susceptibility than those to the S2 (SP=75.0%, SE=66.67%) or N (SP 87.5%, SE=38.9%). Combining thresholds for T-cell S1 and N did not improve performance compared to S1 alone. Conversely, combining T-cell S1 with N-specific pan Ig offered improved specificity with no loss of sensitivity (SP=100%, SE=72.2%). The performances of all threshold combinations are detailed in Figure S11.

209

210 Association between ICS responses to pre-vaccination SARS-CoV-2 infection and BI

To determine whether specific features of the T-cell response to SARS-CoV-2 infections were 211 also a factor in determining risk of BI, pre-vaccination ICS responses were compared in cases 212 213 with and without a reported BI. Monofunctional CD4⁺ and CD8⁺ T cell responses were included 214 in these analyses as these were the predominant responses observed in these individuals. There was no meaningful difference between the magnitude of S, N or NS3PB-specific T-cell responses 215 in the two groups (Figure 4C/D, Figure S8C/D). In contrast, participants who didn't report BIs 216 217 displayed higher magnitudes of SARS-CoV-2 M-specific CD4⁺ and CD8⁺ T-cells, and these were skewed respectively towards production of IFN-v⁺ and CD107a (IFN-v⁺: 40.0%; CD107a: 35.7%; 218 Figure 4E), and CD107a and MIP1ß (CD107a: 42.4%; MIP1ß: 45.0%; Figure 4F), respectively. 219 220 However, including these ICS measures in the analysis did not improve the predictive ability of thresholds generated using antibody and/or T-cell data alone. 221

222

223 DISCUSSION

224 Humoral and cellular immune responses to COVID-19 vaccination were measured in ALSPAC participants with or without a history or serological evidence of SARS-CoV-2 infection. In those 225 with hybrid immunity, we demonstrate a correlation between the magnitude of responses 226 following the second vaccination and protection against BI. The combination of serum S-specific 227 IgG (>666.4 BAU/mL) and N-specific pan Ig (>0.1332 BAU/mL) thresholds identified those who 228 229 didn't report BIs with 100% specificity and 83% sensitivity. Our results suggest that hybrid immunity to SARS-CoV-2 remains effective in protection from reinfection at >15 months post 230 infection and >8 months post second-dose vaccination. The reduced association in control 231 participants alludes to the importance of the greater quality and breath of immune responses 232 233 elicited by SARS-CoV-2 infection compared to vaccination alone.

234

COVID-19 vaccination elicited robust serum anti-S IgG and IgA production in all participants, with 235 236 the case group retaining their baseline immunological advantage as observed in other studies³¹. mRNA vaccination resulted in higher S-specific IgG and IgA compared to the viral vector 237 ChAdOx1, as previously reported³². However, neither vaccine type induced salivary IgA, even in 238 participants with a history of COVID-19 where vaccination has been suggested to boost infection-239 primed responses^{22,33,34}. Reducing or eliminating transmission with vaccines capable of eliciting 240 241 mucosal immunity therefore remains a priority, and a number of candidates are currently in development³⁵. 242

243

244 Consistent with recent papers, COVID-19 vaccines induced S-specific T-cell responses in all 245 participants^{36–38}. An increase in the median frequency of T-cell responses to M, N, and NSP3B 246 was observed in the control group. This was predominantly driven by large increases to all target 247 antigens in a small number of participants, suggestive of SARS-CoV-2 infections in these 248 individuals during the study period. No parallel increases in serum anti-N pan Ig or saliva anti-S 249 IgA were observed. These participants with may therefore have experienced asymptomatic,

abortive SARS-CoV-2 infections which have been shown to boost T-cell responses in the absence of seroconversion²⁹. Alternatively, these data could potentially suggest bystander T-cell activation as a result of vaccination. Antigen-independent bystander activation of T-cells which is likely driven by cytokines, has been widely reported during viral infection^{39,40}, however its occurrence in the context of vaccination remains unclear^{41–45}.

255

Long-term protection against SARS-CoV-2 BI relies upon the durability of vaccine-induced 256 257 responses. Antibodies in particular have been shown to wane rapidly in the 6-months following the primary and subsequent vaccine doses⁴⁶⁻⁴⁸. This declining immunity, particularly in the 258 context of highly transmissible SARS-CoV-2 variants with reduced neutralising sensitivity, 259 increases BI rates^{8,10,49}. Anti-S IgG and neutralising antibody levels have been shown to 260 negatively correlate with the risk of SARS-CoV-2 infection and severe disease^{12,21,50-52}. In control 261 participants, we observed no evidence of difference in the magnitude of responses between 262 those who did and didn't experience BIs, and protective thresholds could therefore not be 263 264 defined. However, anti-S IgG ≥666.4 BAU/mL was associated with reduced incidence of BI in 265 those with a history of SARS-CoV-2 infection. This is consistent with the large Israeli COVID-19 266 family study (ICoFS) which proposed S-specific IgG >500 BAU/mL, and neutralising antibody titres of >1024, as thresholds of protection against SARS-CoV-2 Delta infection ⁵³. IgG levels 267 above this were associated with an 11% probability of infection, and 1% probability of moderate 268 269 disease. ICoFS baseline measurements were taken shortly before infection and therefore their 270 lower threshold value is expected relative to our use of post-vaccination dose 2 titres that were recorded months earlier. Serum anti-S IgA also associated with reduced BIs in our cohort, and 271 alongside mucosal IgA has previously been shown to correlate with protection against infection 272 273 independently of IgG²². Bls experienced shortly after primary vaccination correlated with lower vaccine-induced IgA²², and in those who experienced infections serum IgA levels inversely 274 correlated with symptom duration⁵⁴. Increased S-specific T-cells also correlated with reduced BI 275 in our cohort, consistent with previous reports for both CD4⁺ and CD8⁺ responses^{55,56}. 276

Furthermore, the combination of high neutralizing antibodies and S-specific IFN- γ responses is associated with protection against BI^{57,58}.

279

There is now mounting evidence that hybrid immunity affords more robust and sustained 280 protection against BI compared to vaccine-induced immunity alone^{46,59-62}. Consistent with this, 281 BI rates in our study were lower in cases (30.8%) compared to controls (42.4%). Both humoral 282 and cellular immune responses have been reported to be qualitatively superior in those who 283 experience SARS-CoV-2 infection prior to vaccination^{61,62}, and infection-derived immunity may 284 be particularly important in the context of BIs with novel variants^{23,63}. It is only SARS-CoV-2 285 infection that induces a significant and durable systemic IgA response⁴⁸, and COVID-19 vaccines 286 perform poorly at eliciting mucosal IgA³⁴. Additionally, the increased magnitude of neutralising 287 responses in hybrid immunity enhances the breadth of neutralising activity against divergent 288 variants of concern^{64,65}. Vaccine-induced Fc-receptor binding antibodies are also important for 289 the control and clearance of infection and have also been shown to be more abundant in those 290 291 with a history of COVID-19, with this difference persisting post-vaccination⁶¹.

292

Functional and phenotypic properties of SARS-CoV-2 adaptive immunity appear to differ in 293 response to SARS-CoV-2 infection and COVID-19 vaccination^{66,67}. A skewed T-helper (Th)1 294 SARS-CoV-2-specific T-cell response and higher percentages of IgG-expressing memory B-cells 295 296 were observed in vaccinated individuals compared to individuals who recovered from COVID-297 19⁶⁸. In this study we assessed the functional and phenotypic features of SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells in previously infected individuals prior to vaccination, and compared these 298 in individuals who subsequently did or did not experience Bls. We show trends towards higher 299 300 magnitudes of SARS-CoV2-specific CD8⁺ T-cells targeting S2, N, M and NSP3B in individuals who do not develop BI, with differences being significantly higher only for M, suggesting a 301 protective role for these cells. Similarly, M-specific CD4⁺ T-cells are present at higher magnitudes 302 303 in individuals who do not develop BI compared to those that do. In addition, the former group displays M-specific CD4⁺ T-cells mainly producing IFN-y and CD107a, which suggests a 304

305 protective role of cytotoxic Th1-cells in COVID-19. These data highlight how a granular analysis 306 of CD4⁺/CD8⁺ T-cell responses may inform T-cell features associated with protection in COVID-307 19. This is critical for an integrated definition (incorporating T-cells and antibodies) of 308 correlates/determinants of protective immunity to SARS-CoV-2 and potentially other viral 309 infections.

310

In addition to changing the quality of responses, SARS-CoV-2 infection primes the immune 311 312 system with a broader range of antigens than vaccination. Anti-N seropositivity was strongly associated with protection against reported BIs in our cohort. This corroborates the conclusions 313 of other studies, with previous estimates suggesting that it afforded participants with 314 approximately 80% protection against SARS-CoV-2 re-infection for the subsequent 8-months 69. 315 316 In those experiencing BIs, anti-N seropositivity also associated with a shorter duration and reduced viral load⁵⁴. Evidence suggests that COVID-19 vaccination drives differential responses 317 to subsequent SARS-CoV-2 infection, boosting those primed by the vaccine over new responses 318 to the broader repertoire of proteins in the virus^{54,70-72}. Seroconversion to N upon SARS-CoV-2 319 320 infection was observed at a higher rate in placebo vaccinated participants (93%) compared to mRNA-1273 recipients (40%)⁷⁰. Additionally, SARS-CoV-2 BIs elicit anti-N IgG at significantly 321 lower rates in infection-naïve individuals compared to those with a history of pre-vaccination 322 COVID-19^{54,71,72}. This suggests that the order in which hybrid immunity is achieved may be 323 324 important.

325

SARS-CoV-2 LFT testing of a wider sample of ALSPAC participants highlighted an age-related difference in anti-N positivity rates. By spring 2022, all UK adults had been offered 3 vaccine doses, and this was reflected in comparable anti-S positivity rates of 93.0% and 96.0% in the G0/G1 cohorts respectively. However, only 50.3% of the older generation had a positive anti-N response compared to 67.1% of the younger adults. These values may underestimate SARS-CoV-2 infection rates in the older generation due to the lower N-seroconversion rates in infections occurring post-vaccination. However, they do accurately reflect a lack of potentially protective

333 anti-N antibodies in this population. Prioritising older adults for early vaccination, and 334 encouraging shielding behaviours, may therefore have consequences for the breadth and durability of the immunity they obtain by reducing pre-vaccination infection rates, and overall N-335 336 seroconversion. Rapid vaccination of this age group proved essential for reducing the rates of severe disease and associated mortality, and on a population level these benefits are unlikely to 337 be outweighed by the benefits of a broader infection-primed response. Instead, this highlights 338 339 the importance of designing novel vaccines that prime responses to additional antigens to 340 generate more robust and sustained protection.

341

Our BI susceptibility analysis should be interpreted in the context of the limitations of our study 342 design. Firstly, the sample size was limited by those with available post-dose 2 vaccination 343 344 measures and may not be representative of the whole population. Secondly, with respect to the 345 BI rates in the case and controls groups, differences in exposure risk and test-seeking behaviours which could not be measured or accounted for may have influenced outcomes. Key variables, 346 such as the proportion who received a booster vaccine, were however comparable between 347 348 groups. Thirdly, N-protein serology does not offer 100% sensitivity for detection of new SARS-CoV-2 cases and therefore undetected infections during the study period could have resulted in 349 participants being mis-classified as controls for the BI analysis. Fourthly, samples were not 350 collected at the point of BI and therefore could not be confirmed virologically, nor the SARS-CoV-351 352 2 sequences/variant lineages determined. The BI infection monitoring period covered the 353 boundary of Delta and Omicron being the predominant variants in circulation. For the purposes of this analysis, all SARS-CoV-2 infections have been analysed together, but it is possible that 354 355 variant-specific thresholds for protection may differ. Fifthly, although we report correlations 356 between immune markers and susceptibility to future infection, we cannot exclude the possibility that rather than being directly protective, some may act as proxies for undetermined variables 357 that weren't measured. Finally, sample size limitations prevented the stratification of the BI 358 359 analysis by vaccine type. However, this has previously been shown not to directly influence the 360 susceptibility to BIs. Instead, higher BI rates in ChAdOx1 recipients can be attributed to the lower

immunogenicity of ChAdOx1 resulting in participant IgG levels waning below protective
 thresholds faster than in BNT162b2 recipients¹³.

363

In summary, the data generated here add detail to the evidence of broader immune responses 364 to infection and vaccination beyond the comparatively well-characterised anti-S IgG and 365 neutralising antibody levels as markers of protection against SARS-CoV-2 BIs. Additionally, our 366 findings support the notion that it is not only the magnitude of T-cell responses generated by 367 368 hybrid immunity that improves protection against BI, but also their breadth and guality. This reinforces the need for next generation vaccines that elicit hybrid-mimicking immune responses 369 for more robust and sustained protection. Better understanding the immune markers correlated 370 with protection will also be important for the rapid validation of these new vaccines at a point in 371 372 the pandemic when placebo-controlled vaccine trials are no longer practical.

373

374

375

376 **ACKNOWLEDGEMENTS**

We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses.

381

We wish to acknowledge the assistance of Dr Andrew Herman, Helen Rice, and the University of Bristol Faculty of Health and Life Sciences Flow Cytometry Facility. This work was undertaken with support of the Elizabeth Blackwell Institute (EBI) Mechanisms to Populations Research Strand that promotes interdisciplinary research between fundamental bioscience and population health. The support from the EBI and the University's Alumni and Friends funded the purchase of the CTL ELISpot reader and ELISA microplate washer, and ELISpot peptide pools used in this

study. Thank you to the Bristol UNCOVER group for helpful discussions on assay developmentand the interpretation of results.

390

391 FUNDING

This work was funded by UK Research and Innovation (UKRI) through the UKRI rapid response call for COVID (MR/V028448/1). This work was supported by the Elizabeth Blackwell Institute, University of Bristol, with funding from the Wellcome Trust ISSF3 (204813/Z/16/Z), and the University's Alumni and Friends (LW, LR, AH, AD, AF and OF).

396

NJT is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001), the Medical Research Council (MRC) Integrative Epidemiology Unit (MC_UU_00011/1) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019). MK is supported by the MRC (MR/W021315/1). MS is supported by the Academy of Medical Sciences (Springboard Award SB007\100173).

403

The MRC and the Wellcome Trust (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors; LR, AH, LW, HEB and MS will serve as guarantors for the contents of this paper. A comprehensive list of grant funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grantacknowledgements.pdf). This research was specifically funded by the Wellcome Trust and the MRC (grant 102215/2/13/2). The funders had no role in the study design, data collection, data analysis nor preparation of the manuscript or decision to publish.

411

412 AUTHOR CONTRIBUTIONS

Conceptualisation, AF NJT LW AH LR; Methodology, HEB MS OF EM EO REM AT AH;
Validation, HEB MS OF EM EO AT AF; Formal Analysis, HEB MS OF REM MK AH; Investigation,
HEB MS OF EM KE EO BH DD AT BM; Resources, KG NDB PK AB IB AMT; Data Curation, KN

FR; Writing – Original Draft, HEB MS LW AH LR; Writing – Review and Editing, OF EO REM PK
AG AF NJT; Visualisation, HEB MS OF; Supervision, AMT IB AD AG AF LW AH LR; Project
Administration, JO SR LM LW AH LR; Funding Acquisition, AF SR LM NJT LW AH LR
419
420
421 DECLARATION OF INTERESTS

Adam Finn was a lead investigator on trials of COVID-19 vaccines funded by Oxford/Astrazeneca, Valneva and Sanofi and the UK government. He also leads a University of Bristol sponsored epidemiological study of adult respiratory disease funded by Pfizer which has evaluated COVID-19 vaccine effectiveness. During the pandemic he was a member of the Joint Committee on Vaccination and Immunisation which advised the UK government on COVID-19 vaccine policy and of the WHO Specialist Advisory Group of Experts COVID-19 vaccine working group. No other authors declare competing interests.

429

430

431

432 Figure 1: Study design

(A) Participants from the Avon Longitudinal Study of Parents and Children (ALSPAC) were
screened for SARS-CoV-2-specific anti-Spike IgG in October 2020, prior to the vaccine rollout.
Both the G0 (48-70 years) and G1 (29-30 years) generations were eligible for screening. Further
sampling was conducted in June 2021 and June 2022 for both anti-Spike and anti-N IgG.
Numbers indicate the total valid tests, with the percentages indicating the positivity rates.

438

(B) Of those tested in October 2020, 377 were recruited to this study and attended one or more
clinics from December 2020 to June 2021, providing biological samples, and completing health
questionnaires. During this period, participants became eligible to receive COVID-19 vaccines
via the UK national vaccination programme (blue text indicates % vaccinated at each clinic).

Following the sampling period, participants continued to complete online questionnaires detailing
their LFT and PCR-confirmed SARS-CoV-2 infections.

445

446

Figure 2: Antibody and T-cell responses to COVID-19 vaccination in SARS-CoV-2 naïve and previously infected individuals.

(A) Participants were classified as cases based on a previous PCR-confirmed SARS-CoV-2
infection and/or positivity on serum anti-Spike and/or anti-Nucleocapsid pan Ig ELISAs. (B)
Serum pseudoneutralising antibody titres. (C/D) Anti-Spike IgG and IgA in serum and saliva,
measured by ELISA. Correlation coefficients calculated using Spearman's rank (rs). (E)
Magnitude of SARS-CoV-2-specific T-cell responses against Spike-1, Spike-2, N, M and NSP3B
peptide pools measured by ELISpot assay.

455

Red bars indicate median responses. Unpaired comparisons were performed using Kruskal-Wallis test with Dunn's correction for multiple comparisons. Within each of the case and control groups, responses were compared between 0 and 1, and 1 and 2 vaccine doses. Responses between groups were compared after each dose. Statistics are only displayed for comparisons where P ≤ 0.05 (*), ≤ 0.01 (**), ≤ 0.001 (***), ≤ 0.0001 (****).

461

462

Figure 3: SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cell responses in previously infected individuals.

Graphs show the percentage of CD4⁺ (A) and CD8⁺ (B) T-cells producing the indicated cytokine or combination of cytokines after a brief stimulation with Spike-1, Spike-2, M, N or NSP3B peptide pools, assessed by intracellular cytokine staining and flow cytometry. Pie charts indicate the proportion of T-cells, within total cytokine⁺ T-cells, that producing each cytokine (colour-coded) and that display one or more functions (black/grey). Statistics from monofunctional SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells in previously infected individuals were calculated using a

Kruskal-Wallis test with FDR method of Hochberg correction 471 Benjamini and 472 for multiple comparisons. P-values are reported in Table S2. 473 474 Figure 4: Association between immune responses to prior SARS-CoV-2 infection and 475 COVID-19 vaccination and susceptibility to SARS-CoV-2 breakthrough infection 476 (A/B) Correlation of post-second vaccination antibody and T-cell responses in participants who 477 self-reported a SARS-CoV-2 infection in the subsequent 8-months (breakthrough infection; BI) 478 and those who didn't (no BI). (A) SARS-CoV-2-naïve individuals (with BI n=14; no BI n=19). (B) 479 Previously SARS-CoV-2-infected individuals (BI n=8, no BI n=18). See Figure S10 for derivation 480 481 of thresholds. 482 (C-F) Correlation of pre-vaccination SARS-CoV-2-specific T-cell intracellular cytokine responses 483 in cases with subsequent BI. (C/D) Magnitude of baseline (pre-vaccination) single 484 cytokine/CD107a-producing (monofunctional) SARS-CoV-2-specific CD4⁺ (C; n=47) and CD8⁺ 485 486 (D; n=51) T-cells specific for the indicated SARS-CoV-2 proteins among cases. Red bars represent median responses. Statistics calculated by t-test (Mann-Whitney). (E/F) Proportions of 487 single cytokine/CD107a-producing CD4⁺ (n=40) and CD8⁺ (n=43) T-cells within the respective 488 M-specific T-cell population. 489 490 491 492 METHODS 493 494 ALSPAC The Avon Longitudinal Study of Parents and Children (ALSPAC) is a birth cohort study ^{73–76}. 495 Pregnant women resident in Avon, UK with expected dates of delivery between 1st April 1991 496 497 and 31st December 1992 were invited to take part. A total of 14,541 pregnancies were initially

498 enrolled, with 13,988 children who were alive at 1 year of age. ALSPAC now comprises three

499 generations: the original pregnant women with the biological fathers and other carers/partners 500 (G0), the cohort of index children (G1), and the offspring of the index children (G2). This has generated a wealth of biological, genetic and phenotypic data spanning the lifetime of these 501 502 individuals. Including additional participants recruited in the interim period, the total sample size for analyses using any data collected after the age of seven is 15,447 pregnancies, resulting in 503 15,658 foetuses. Of these 14,901 children were alive at 1 year of age. 12,113 G0 partners have 504 been in contact with the study, of which 3,807 are currently enrolled. Please note that the study 505 506 website contains details of all the data that are available through a fully searchable data dictionary and variable search tool ⁷⁷. From the beginning of the COVID-19 pandemic, ALSPAC sought to 507 utilise their unique expertise and infrastructure to contribute to SARS-CoV-2 research efforts 508 509 through collection of biological samples and questionnaire data from their cohort of well 510 characterised participants.

511

512 Study design

In October 2020, ALSPAC undertook 5200 serological SARS-CoV-2 spike-specific lateral flow 513 514 tests (Fortress Diagnostics, Antrim Northern Ireland) on G0 and G1 cohort participants 78. Participants with evidence of a previous SARS-CoV-2 infection based on a positive IgG result on 515 this LFT, and/or a positive SARS-CoV-2 PCR result from linked UK Health Security Agency 516 (UKHSA) data, were invited to take part in the study (n=124). Two control groups with negative 517 518 serological results, and no documented positive PCR test, were recruited alongside these 519 participants. The first control group (n=93) were also age, sex, and symptom (anosmia) matched to those with a history of SARS-CoV-2 infection. Participants in the second control group (n=103) 520 were selected on the basis of not having reported anosmia. Full details of the recruitment 521 522 methodology, alongside a detailed characterisation of the cohort at clinic 1 (pre-vaccination), are described in Mitchell et al ³⁰. In brief, participants attended up to 3 clinics in December 2020 523 (clinic 1), March 2021 (clinic 2) and June 2021 (clinic 3) where they provided venous blood and 524 525 saliva samples. Additional participants were recruited at clinics 2 and 3 to maintain numbers and 526 account for those who withdrew from the study. Health and lifestyle information was gathered

through online questionnaires. For the purposes of the analyses presented in this study, the two
 control groups have been combined as no significant differences in baseline antibody or T-cell
 measures were detected between the two original groups ³⁰.

530

531 *Ethics*

Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees (NHS REC 20/HRA/4854). Consent for biological samples was collected in accordance with the Human Tissue Act (2004). Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time.

537

At age 18, study children were sent 'fair processing' materials describing ALSPAC's intended use of their health and administrative records and were given clear means to consent or object via a written form. Data were not extracted for participants who objected, or who were not sent fair processing materials. Ethical approval was obtained from the ALSPAC Law and Ethics committee and local research ethics committees (NHS Haydock REC 10/H1010/70).

543

544 Sample collection and processing

Peripheral blood mononuclear cells (PBMCs) were obtained from up to 3 x 10 ml EDTA tubes 545 546 per participant using standard density gradient separation techniques. Briefly, samples were kept 547 at room temperature for up to 3 hours after drawing blood. Blood was diluted 1:1 with Phosphate Buffered Saline (PBS) containing 1% Fetal calf serum (FCS). Diluted blood was separated using 548 a Ficoll gradient, centrifuging at 1000g for 10 mins at room temperature. PBMCs were washed 549 550 in PBS/1% FCS, centrifuging at 700g for 10 mins at room temperature, and washed again with PBS/1% FCS, centrifuging at 400g for 10 mins at room temperature. Cell pellets were 551 resuspended in freezing mix (90% FCS/10% DMSO) at a concentration of 13-15x10⁶ cells per 552 553 mL. Cells were frozen overnight in an alcohol bath to control freezing rate. PBMCs were then 554 transferred to liquid nitrogen cryotanks for long-term storage. Serum tubes were left to clot,

centrifuged at 1,500g for 10 mins at 18-25°C, then serum was removed, aliquoted, and stored at
-80 °C.

557

Participants provided neat saliva directly into a sterile collection tube. Particulate matter was
removed by centrifugation at 13,000g for 10 minutes. Samples were heat-inactivated at 56°C for
30 minutes prior to ELISA analysis.

561

562 **ELISAs**

SARS-CoV-2-specific anti-Spike (S) IgA and IgG in serum and saliva were measured by ELISA. 563 Samples were run in duplicate at a single optimised dilution and reported in BAU/mL following 564 565 calibration of an internal standard to the WHO/NIBSC reference control. Serum anti-nucleocapsid 566 (N) and anti-S pan Ig were utilised as screening ELISAs to report a positive/negative result for previous SARS-CoV-2 infection with data presented as normalised optical density (OD) 567 measurement relative to an internal control. Thresholds for positivity were calculated on a large 568 sample of PCR-confirmed and pre-pandemic samples. Full details of these methods are 569 published for serum ⁷⁹, and saliva ⁸⁰, respectively. 570

571

572 Synthetic peptides

Peptides used for PBMC stimulations in the ELISpot assays are listed in Supplementary Table 573 574 S1. 15-mer peptides overlapping by 10 amino acids and spanning the sequences of the SARS-575 CoV-2 S, N, Membrane (M) and Envelope (E) protein were purchased from Mimotopes (Australia). The purity of the peptides was >80%. 15-18mer peptides overlapping by 10 amino 576 acids and spanning sequences of SARS-CoV-2 NSP1-16, ORF3, ORF6, ORF7 and ORF8 were 577 578 also purchased). The purity of the peptides was ~70%. The combination of peptides and identity of the peptide pools are described in Methods Table 1. For PBMC stimulation in ELISpot assays, 579 pools of a maximum of 127 peptides were added per well as follows: Spike was divided into 2 580 581 pools (S1; 126 peptides and S2; 127 peptides); for smaller peptide regions, peptides were combined in the same peptide pools as follows: NSP1 and NSP2 (NSP1+2), NSP5 and NSP6 582

(NSP5+6), NSP15 and NSP16 (NSP15+16). All other peptides were pooled into one mixture and
tested in individual ELISpot wells.

585

586 Enzyme-linked immune absorbent spot assay (ELISpot)

Human IFN-y ELISpot assays were performed using a Human IFN-y ELISpot BASIC kit 587 (Mabtech). MSIP4W10 PVDF plates (Millipore) were coated with capture antibody (mAb-1-D1K; 588 15 µg/mL) and incubated overnight at 4 °C in carbonate bicarbonate buffer (Sigma Aldrich). 589 590 Cryopreserved PBMC were thawed then rested at 37 °C/5% CO₂ for 5-6 hours. Coated plates 591 were washed 5 times in sterile PBS and blocked for 1-2 hours using R10 medium (0.2 µm filtered RPMI 1640 medium supplemented with 10 % FBS, 2 mM glutamine, penicillin ((100 units/ml) and 592 streptomycin (100 µg/ml)). 4 x 10⁵ PBMCs were added to each well in the plate, with or without 593 594 peptide pools (as indicated) in a total assay volume of 100 µl in R10. PBMC incubated with R10 595 medium alone were used as negative (unstimulated) controls and were performed in duplicate. 596 Peptide pools spanning S1, S2, M, N, E, ORF1 (NSP1+2, NSP3A, NSP3B, NSP3C, NSP4, NSP5+6, NSP7-11, NSP12A, NSP12B, NSP13, NSP14, NSP15+16), ORF3, ORF6, ORF7 and 597 598 ORF8 were used at a final concentration of 2 µg/ml. PBMCs from cases were tested against all the above peptide pools, while PBMCs from controls were tested against the following peptide 599 pools only: S1, S2, M, N, NSP3B, NSP12A, NSP12B, NSP7-11, NSP13 and NSP15+16. PBMC 600 stimulated with anti-CD3 antibody (Mabtech, Mab CD3-2; final concentration 0.1% v/v) were used 601 602 as a positive control for each participant, with 1-4 x 10⁵ PBMCs used per well. Positive control 603 and peptide stimulated wells were performed in singlet. Plates were incubated for 16-18 hours at 37°C/5% CO₂ then developed as per manufacturer's instructions. Developed plates were 604 605 protected from light and air-dried for 48 hours before image acquisition using a CTL ImmunoSpot 606 S6 Ultra-V Analyzer. Spot forming units (SFU) were calculated using the ImmunoSpot S6 Ultra-607 V Analyzer Basic Count function after image acquisition using optimised counting parameters 608 that were applied across all participants. Spot counts were enumerated for each peptide pool by 609 subtraction of average background (calculated from duplicate unstimulated wells). Counts were expressed as SFU per million (106) PBMC after multiplication by 2.5 following background 610

subtraction. Negative values after background subtraction were adjusted to zero ²⁹. Participants 611 612 were excluded if the spot count in unstimulated wells exceeded 95 SFU per million PBMC or if no spots were observed in the positive control wells. Where spot formation was too dense to 613 614 accurately enumerate using standardised counting parameters (TNTC; too numerous to count), affected wells were excluded unless contemporaneous assessment of IFN-y production by flow 615 cytometry confirmed antigen specific response. In these cases, TNTC values were given the raw 616 value equivalent to the largest spot count accurately counted for a peptide pool (320 SFU per 617 618 well).

619

620 Intracellular Cytokine Staining (ICS)

PBMCs were thawed and rested overnight in AIMV 2% FCS then incubated with or without 621 peptide pools from SARS-CoV-2 S1/S2, M, N, NSP3B (all 1 µg/ml), or with PMA/ionomycin (PMA 622 10 ng/ml, ionomycin 100 ng/ml, Sigma-Aldrich) for 5 hr at 37°C in the presence of brefeldin A 623 (BD, 5 µg/ml). To assess degranulation, anti CD107a-FITC antibody was added to the cells at 624 the beginning of the stimulation. Cells were stained with a viability dye Zombie Agua (BioLegend) 625 for 10 min at room temperature and then with antibodies targeting surface markers (20 min 4°C, 626 diluted in PBS 1% BSA; Sigma-Aldrich). Cells were fixed overnight in eBioscience 627 Foxp3/Transcription factor fixation/permeabilization buffer (Invitrogen), and intracellular staining 628 was performed for detection intracellular cytokines, including IFN-y, TNF- α , IL-2 and MIP1 β (30 629 630 min 4°C). Four samples were excluded from further CD4⁺ T-cell analysis due technical issues. 631 Data were acquired on a BD LSR Fortessa X20 and analysed using FlowJo software v10.8.1. Results were obtained after subtraction of the values in the corresponding unstimulated well. A 632 complete list of antibodies is included in Methods Table 2. ICS was performed on samples from 633 634 69 individuals in the case group, selected based on having a detectable T-cell response by IFNv ELISpot at baseline (i.e. clinic one) for at least one of the SARS-CoV-2 peptide pools tested 635 and for whom we had additional cryopreserved PBMC vials available at baseline. 636

637

638 **Pseudoneutralisation**

639 Serum neutralisation was expected to positively correlate with levels of anti-Spike antibody 640 binding results. Accordingly, all samples from participants in the case group corresponding to 641 anti-Spike pan-Ig ELISA results above a normalised threshold of 0.5 were included. For pseudovirus assays, Wuhan-Spike-harbouring pseudovirus (luciferase-expressing vesicular 642 stomatitis virus, VSV-S-FLuc) was generated and used to assess serum antibody neutralisation 643 of VSV-S-FLuc entry into Vero ACE2 TMPRSS2 (VAT) cells as described previously ⁷⁹. Briefly, 644 645 serum dilutions starting at 1/40 followed by eight 2.5-fold titrations were plated in triplicate in 96well plates, alongside three wells each of 1/25 dilutions of known neutralising and non-646 neutralising controls (corresponding to 16,000 RLU of luminescence when mixed with VSV-S-647 FLuc). WT Wuhan spike pseudotyped VSV was added to each well and incubated for an hour. 648 649 Well-mixtures were added to black, microscopy 96-well plates, seeded with 10,000 Vero ACE2 TMPRSS2 (VAT) cells per well. Luminescence measurements were taken 16 hours after 650 infection, using the ONE-Glo Luciferase Assay System. 651

652

653 Data analysis

Study data were collected and managed using REDCap (Research Electronic Data Capture)
electronic data capture tools hosted at the University of Bristol. REDCap is a secure, web-based
software platform designed to support data capture for research studies ⁸¹.

657

Participant data was excluded from the analysis if it was subsequently established that a participant was vaccinated as part of an unlicensed COVID-19 vaccine trial prior to enrolment in this study. In order to focus on the immune responses to COVID-19 vaccines, data was also removed if no corresponding information provided on the COVID-19 vaccination status of the participant at a particular clinic visit. Where a participant provided samples at more than one clinic after a specified number of vaccine doses (including pre-vaccination), only the data from the earliest sampling clinic was included in the analysis.

665

666	Statistical analyses were performed using R Studio (v4.3.0), and GraphPad Prism (version
667	10.01). Unpaired comparisons across multiple groups were done with the Kruskal-Wallis test with
668	Dunn's post-test for multiple comparisons. Pairwise correlations were assessed with Spearman's
669	rank-order correlation (r_s). Correlation coefficients were interpreted as: weak (r_s =0.20-0.39),
670	moderate (r_s =0.40-0.59), strong (r_s =0.60-0.79), or very strong (r_s =0.80-1.00). The following
671	adjusted P value thresholds were used for data visualisation: P≤0.05 (*), P≤0.01 (**), P≤0.001
672	(***), P≤0.0001 (****). To facilitate the presentation of data which included zero counts on log
673	scales, zero counts were plotted as 1 (or the minimum y axis baseline, if lower) for visualisation
674	purposes only – all statistical analyses were performed on the raw data values.
675	
676	
677	
678	
679	
680	
681	
682	
683	
684	
685	
686	
687	
688	
689	
690	
691	
692	Table S1: Participant demographics

- To protect participant anonymity, specific values for counts fewer than 5 are not provided. Please
 note that fields marked as < 5 may include zero.
- 695

Table S2: Statistical comparison of monofunctional SARS-CoV-2-specific CD4⁺ and CD8⁺

- 697 **T-cells in previously infected individuals.**
- Statistics from monofunctional SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells in previously
 infected individuals as presented in Figure 3. Calculated using a Kruskal-Wallis test with FDR
 method of Benjamini and Hochberg correction for multiple comparisons.
- 701

702 **Table S3: Characteristics of the infection susceptibility groups.**

Participants were classified as cases based on a PCR-confirmed SARS-CoV-2 infection prior to their second vaccine dose, and/or positivity on the serum anti-Spike and/or anti-Nucleocapsid protein pan Ig screening ELISAs at clinic 1 (prior to vaccination). In each of the case and controls groups, participants were stratified into those who did and didn't self-report a SARS-CoV-2 infection in the 8 months after clinic 3 (July 2021 – March 2022).

708

Participants self-reported information on whether they identified as having a weakened immune system / increased susceptibility to infection at the beginning of the pandemic (April 2020). Data on behavioural modifications were collected at the end of the breakthrough infection monitoring period (March 2022). Participants self-reported whether they felt they had been limiting their social contacts prior to meeting friends or relatives, and whether they had been shopping online rather than visiting stores.

715

716 Supplementary Figure 1: Participants inclusion flowchart.

All G0 (original mothers and partners) and G1 (offspring generation) ALSPAC participants were eligible to voluntarily enrol in this study. Participant data was subsequently excluded from the analysis if they reported a previous COVID-19 vaccination. In order to focus on the immune responses to COVID-19 vaccines, data was also removed if there was no corresponding

information provided on the COVID-19 vaccination status of the participant at a particulartimepoint.

723

Supplementary Figure 2: Anti-N pan Ig levels in control participants before and after vaccine dose 1.

Serum anti-Nucleocapsid (N) pan Ig antibody levels in serum were measured by in-house ELISA. Results are presented as normalised OD relative to an internal control. Data shown represent all participants classified as controls with data available both before and after the first vaccine dose (n=95). Participants with a \geq 2-fold increase in N pan Ig levels from baseline to post-dose 1 are highlighted in red (n=3). Responses before and after vaccination were compared using a Mann Whitney test.

732

733 Supplementary Figure 3: Correlation between SARS-CoV-2 Spike-specific serum IgG and 734 pseduoneutralising antibody levels.

Anti-Spike IgG levels in serum were measured by in-house ELISA and reported in BAU/mL following calibration of the assay to the WHO/NIBSC reference standard. Pseudoneutralising antibody titres against ancestral Spike were measured in serum. Spearman's rank (r_s) correlations were calculated at baseline (white; n=99), post dose 1 (grey; n=61) and post dose 2 (blue; n=49). P values were categorised as ≤0.05 (*), ≤0.01 (**), ≤0.001 (***), ≤0.0001 (****).

740

741 Supplementary Figure 4: Antibody and T cell responses by COVID-19 vaccination type.

Participants were stratified based upon the type of COVID vaccine received; AstraZeneca ChAdOx1 whole virion vaccine, or one of two mRNA-based vaccines (Pfizer/BioNtech BNT162b2 or Moderna mRNA-1273). All participants received homologous first and second doses. (A) Antibody levels in serum and saliva were measured by in-house ELISA. Assay thresholds were set using samples taken following recent SARS-CoV-2 infection and pre-pandemic controls to achieve 99% specificity. Results are reported in binding antibody units (BAU)/mL following calibration of the assay to the WHO/NIBSC reference standard. (B) Magnitude of SARS-CoV-2

749 specific T cell response against Spike (pool-1 and 2) peptide pools measured via ELISpot assay. Shown are comparison of cells producing IFN-y after stimulation of PBMCs with 750 751 overlapping peptides spanning the indicated proteins. Results are expressed as Spot Forming Units (SPU) relative to 1x10⁶ PBMCs after subtraction of average background (calculated from 752 duplicate unstimulated wells). Negative values after background subtraction were adjusted to 753 zero. Participants were excluded from the dataset due to high background (>95 SFU per million 754 PBMC). White = baseline measurement; grey = post vaccine dose 1; blue = post vaccine dose 755 756 2. Red bars represent the median of each group. Unpaired comparisons were performed using Kruskal-Wallis test with Dunn's correction for multiple comparisons. Within each of the case and 757 control groups, responses were compared between 0 and 1, and 1 and 2 vaccine doses. 758 759 Responses between groups were compared after each dose. Statistics are only displayed for comparisons where P \leq 0.05. P values were categorised as \leq 0.05 (*), \leq 0.01 (**), \leq 0.001 (***), 760 ≤0.0001 (****). 761

762

763 Supplementary Figure 5: Magnitude of T-cell response following COVID-19 vaccination

764 Ex-vivo IFN-y ELISpots showing the overall magnitude and breadth of effector T-cell responses to SARS-CoV-2 proteins following vaccination. (A) Responses in cases (n=108), and (B) 765 responses in controls (n=132). Results are expressed as Spot Forming Units (SFU) per 766 767 1x10⁶ PBMCs after subtraction of average background (calculated from duplicate unstimulated 768 wells). Red bars represent median T-cell responses. Structural proteins: Spike (S1 and S2), M, 769 N and E, non-structural: NSP1-2, NSP3A, NSP3B, NSP3C, NSP4, NSP5-6, NSP7-11, NSP12A, NSP12B, NSP13, NSP14 and NSP15-16, and accessory proteins: ORF3, ORF6, ORF7 and 770 ORF8. Significance was determined using a Kruskal-Wallis test with Dunn's correction 771 772 for multiple comparisons; where P ≤0.05 (*), ≤0.01 (**), ≤0.001 (***), ≤0.0001 (****).

773

Supplementary Figure 6: Gating-strategy for the identification of SARS-CoV-2-reactive cytokine producing CD4⁺ and CD8⁺ T-cells

PBMCs were stimulated with SARS-CoV-2-overlapping-peptide-pools (Spike, M, N and NSP3B) for 6h after overnight resting. The gating strategy for CD4⁺ and CD8⁺ T-cells is shown panel A. Dot plots are representative of cytokine secretion by CD4⁺ T-cells (B) and CD8⁺ T-cells (C) specific for the Membrane (M) protein. These cells were further analysed for the expression of interleukin (IL) 2, interferon γ (IFN-γ), tumour necrosis factor (TNFα), MIP1β and degranulation (CD107a) (panel B/C). The unstained control and PMA/I stimulated sample were used as a negative and positive control for ICS assay, respectively (D).

783

Supplementary Figure 7: Frequency of monofunctional SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells in previously infected individuals.

Percentage of cytokine-producing T-cells was measured by intracellular cytokine staining and flow cytometry. Shown are the percentages of monofunctional CD4⁺ (A) and CD8⁺ (B) T-cells producing IFN- γ , TNF α IL-2, MIP1 β or CD107a (single positive for each) after stimulation with the indicated SARS-CoV-2 peptide pools. Statistics were calculated using a Kruskal-Wallis test with Dunn's correction for multiple comparisons; where P ≤0.05 (*), ≤0.01 (**), ≤0.001 (***), ≤0.0001 (****).

792

Supplementary Figure 8: Frequency of polyfunctional SARS-CoV-2-specific CD4⁺ and CD8⁺T-cells in previously infected individuals.

(A-B) Frequency of polyfunctional SARS-CoV-2-specific CD4⁺ (left panel) and CD8⁺ (right panel)
T-cells targeting peptide pools from Spike and non-Spike proteins (M, N and NSP3B). Statistics
were determined using a Kruskal-Wallis test with Dunn's correction for multiple comparisons. (CD) Frequency of polyfunctional SARS-CoV-2-specific CD4⁺ (left panel) and CD8⁺ (right panel) Tcells targeting SARS-CoV-2 peptide pools in individuals who experienced BI infection versus
those who did not. Red bars represent median responses. Statistics were calculated by ttest (Mann-Whitney test).

802

803 Supplementary Figure 9: Comparison of post-vaccination dose 2 antibody and T-cell 804 levels in participants with and without a reported SARS-CoV-2 breakthrough infection.

Post-second vaccination immune responses in participants who self-reported a SARS-CoV-2 infection in the subsequent 8-months (breakthrough infection; BI) and those who did not (no breakthrough infection). (A) SARS-CoV-2-naïve individuals with (n=14) or without (n=19) a BI. (B) Previously SARS-CoV-2-infected individuals with (n=8) or without (n=18) a BI. Bars represent the median response. Groups were compared using a Mann-Whitney test, with statistics categorised as: P >0.05 (ns), P ≤0.05 (*), ≤0.01 (**), ≤0.001 (***), ≤0.0001 (****).

811

812 Supplementary Figure 10: Breakthrough infection susceptibility threshold setting

813 Participants with a history of SARS-CoV-2 infection were stratified into two groups based upon 814 whether they went on to be re-infected in the 8-month period after the study end date (had a breakthrough infection: yes /no). Receiver Operator Characteristic (ROC) curves were plotted for 815 serum and saliva binding antibody measures (A), serum pseudoneutralising antibody (B), and 816 IFN-y producing T-cells (C). Youden's index thresholds were then calculated for each individual 817 818 measure and are represented by the blue dotted lines on each graph. The sensitivity and specificity parameters for each threshold are presented alongside 95% confidence intervals 819 calculated using the Wilson/Brown method. AUC; area under curve, SE; sensitivity, SP; 820 specificity. Yes BI (n=8), no BI (n=18). 821

822

Supplementary Figure 11: Performance of combined thresholds for breakthrough infection susceptibility.

Participants with a history of SARS-CoV-2 infection were stratified into two groups based upon whether they went on to be re-infected in the 8-month period after the study end date (had a breakthrough infection, BI). Thresholds antibody and T-cell levels that were associated with protection against breakthrough infection were calculated using the Youden's index method (figure S10 for full derivation). Values represent the specificity (SP) and sensitivity (SE) estimates for combinations of two individual thresholds. medRxiv preprint doi: https://doi.org/10.1101/2024.06.14.24308948; this version posted August 8, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

5	R	3	1	

- 831
- 832
- 833

840

- 834 **REFERENCES**
- Fink, Gunther, Tediosi, F., and Felder, S. (2022). Burden of Covid-19 restrictions: National, regional and global estimates. https://doi.org/10.1016/j.
 Thompson, E.J., Williams, D.M., Walker, A.J., Mitchell, R.E., Niedzwiedz, C.L., Yang, T.C., Huggins, C.F., Kwong, A.S.F., Silverwood, R.J., Di Gessa, G., et al. (2022). Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat
 - burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun 13. https://doi.org/10.1038/s41467-022-30836-0.
- Richards, F., Kodjamanova, P., Chen, X., Li, N., Atanasov, P., Bennetts, L., Patterson, B.J.,
 Yektashenas, B., Mesa-Frias, M., Tronczynski, K., et al. (2022). Economic Burden of
 COVID-19: A Systematic Review. Preprint at Dove Medical Press Ltd,
 https://doi.org/10.2147/CEOR.S338225 https://doi.org/10.2147/CEOR.S338225.
- 4. Wang, H., Zeng, W., Kabubei, K.M., Rasanathan, J.J.K., Kazungu, J., Ginindza, S., Mtshali,
 S., Salinas, L.E., McClelland, A., Buissonniere, M., et al. (2023). Modelling the economic
 burden of SARS-CoV-2 infection in health care workers in four countries. Nat Commun 14.
 https://doi.org/10.1038/s41467-023-38477-7.
- 849
 5. Hu, F.H., Jia, Y.J., Zhao, D.Y., Fu, X.L., Zhang, W.Q., Tang, W., Hu, S.Q., Wu, H., Ge, M.W.,
 850
 851
 851
 852
 852
 853
 853
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854
 854</li
- 855
 6.
 Hu, B., Guo, H., Zhou, P., and Shi, Z.L. (2021). Characteristics of SARS-CoV-2 and COVID

 856
 19. Preprint at Nature Research, https://doi.org/10.1038/s41579-020-00459-7

 857
 https://doi.org/10.1038/s41579-020-00459-7.
- Rahman, Md.O., Kamigaki, T., Thandar, M.M., Haruyama, R., Yan, F., Shibamura-Fujiogi,
 M., Khin Maung Soe, J., Islam, Md.R., Yoneoka, D., Miyahara, R., et al. (2023). Protection
 of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron
 subvariant: a systematic review and meta-analysis. BMJ Open *13*, e076892.
 https://doi.org/10.1136/bmjopen-2023-076892.
- 863 8. Feikin, D.R., Higdon, M.M., Abu-Raddad, L.J., Andrews, N., Araos, R., Goldberg, Y.,
 864 Groome, M.J., Huppert, A., O'Brien, K.L., Smith, P.G., et al. (2022). Duration of
 865 effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a
 866 systematic review and meta-regression. The Lancet *399*, 924–944.
 867 https://doi.org/10.1016/S0140-6736(22)00152-0.
- Wu, N., Joyal-Desmarais, K., Ribeiro, P.A.B., Vieira, A.M., Stojanovic, J., Sanuade, C., Yip,
 D., and Bacon, S.L. (2023). Long-term effectiveness of COVID-19 vaccines against
 infections, hospitalisations, and mortality in adults: findings from a rapid living systematic
 evidence synthesis and meta-analysis up to December, 2022. Lancet Respir Med *11*, 439–
 452. https://doi.org/10.1016/S2213-2600(23)00015-2.
- 87310.Desantis, S.M., Yaseen, A., Hao, T., León-Novelo, L., Talebi, Y., Valerio-Shewmaker, M.A.,874Pinzon Gomez, C.L., Messiah, S.E., Kohl, H.W., Kelder, S.H., et al. (2023). Incidence and875Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 after876Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants.877Journal of Infectious Diseases 227, 1164–1172. https://doi.org/10.1093/infdis/jiad020.

878	11.	Piñana, J.L., Vazquez, L., Calabuig, M., López-Corral, L., Martin-Martin, G., Villalon, L.,
879		Sanz-Linares, G., Conesa-Garcia, V., Sanchez-Salinas, A., Gago, B., et al. (2023). One-year
880		breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated
881		hematological patients. Blood Cancer J 13. https://doi.org/10.1038/s41408-022-00778-3.
882	12.	Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M.,
883		Levin, E.G., Rubin, C., Indenbaum, V., et al. (2021). Covid-19 Breakthrough Infections in
884		Vaccinated Health Care Workers. New England Journal of Medicine 385, 1474–1484.
885		https://doi.org/10.1056/nejmoa2109072.
886	13.	Aldridge, R.W., Yavlinsky, A., Nguyen, V., Eyre, M.T., Shrotri, M., Navaratnam, A.M.D.,
887		Beale, S., Braithwaite, I., Byrne, T., Kovar, J., et al. (2022). SARS-CoV-2 antibodies and
888		breakthrough infections in the Virus Watch cohort. Nat Commun 13.
889		https://doi.org/10.1038/s41467-022-32265-5.
890	14.	Moss, P. (2022). The T cell immune response against SARS-CoV-2. Preprint at Nature
891		Research, https://doi.org/10.1038/s41590-021-01122-w https://doi.org/10.1038/s41590-
892		021-01122-w.
893	15.	Ma, H., Zeng, W., He, H., Zhao, D., Jiang, D., Zhou, P., Cheng, L., Li, Y., Ma, X., and Jin, T.
894		(2020). Serum IgA, IgM, and IgG responses in COVID-19. Preprint at Springer Nature,
895		https://doi.org/10.1038/s41423-020-0474-z https://doi.org/10.1038/s41423-020-0474-z.
896	16.	Chia, W.N., Zhu, F., Ong, S.W.X., Young, B.E., Fong, S.W., Le Bert, N., Tan, C.W., Tiu, C.,
897		Zhang, J., Tan, S.Y., et al. (2021). Dynamics of SARS-CoV-2 neutralising antibody responses
898		and duration of immunity: a longitudinal study. Lancet Microbe 2, e240–e249.
899		https://doi.org/10.1016/S2666-5247(21)00025-2.
900	17.	Montague, B.T., Wipperman, M.F., Chio, E., Crow, R., Hooper, A.T., O'Brien, M.P., and
901		Simões, E.A.F. (2022). Elevated serum IgA following vaccination against SARS-CoV-2 in a
902		cohort of high-risk first responders. Sci Rep 12. https://doi.org/10.1038/s41598-022-
903		19095-7.
904	18.	Yang, Z.R., Jiang, Y.W., Li, F.X., Liu, D., Lin, T.F., Zhao, Z.Y., Wei, C., Jin, Q.Y., Li, X.M., Jia,
905		Y.X., et al. (2023). Efficacy of SARS-CoV-2 vaccines and the dose–response relationship
906		with three major antibodies: a systematic review and meta-analysis of randomised
907		controlled trials. Lancet Microbe 4, e236–e246. https://doi.org/10.1016/S2666-
908		5247(22)00390-1.
909	19.	Maringer, Y., Nelde, A., Schroeder, S.M., Schuhmacher, J., Hörber, S., Peter, A., Karbach,
910		J., Jäger, E., and Walz, J.S. (2022). Durable spike-specific T cell responses after different
911		COVID-19 vaccination regimens are not further enhanced by booster vaccination.
912	20.	Earle, K.A., Ambrosino, D.M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P.B., Siber, G.R.,
913		Dull, P., and Plotkin, S.A. (2021). Evidence for antibody as a protective correlate for
914		COVID-19 vaccines. Vaccine <i>39</i> , 4423–4428.
915		https://doi.org/10.1016/j.vaccine.2021.05.063.
916	21.	Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Subbarao,
917		K., Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing antibody levels are
918		highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat
919		Med 27, 1205–1211. https://doi.org/10.1038/s41591-021-01377-8.
920	22.	Sheikh-Mohamed, S., Isho, B., Chao, G.Y.C., Zuo, M., Cohen, C., Lustig, Y., Nahass, G.R.,
921		Salomon-Shulman, R.E., Blacker, G., Fazel-Zarandi, M., et al. (2022). Systemic and
922		mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination
923		and are associated with protection against subsequent infection. Mucosal Immunol 15,
924		799–808. https://doi.org/10.1038/s41385-022-00511-0.
925	23.	Goh, Y.S., Fong, SW., Hor, P.X., Loh, C.Y., Wang, B., Salleh, S.N.M., Ngoh, E.Z.X., Lee,
926		R.T.C., Poh, X.Y., Rao, S., et al. (2023). Variant-Specific IgA Protects Against Omicron
927		Infection. J Infect Dis. https://doi.org/10.1093/infdis/jiad525.
928	24.	Havervall, S., Marking, U., Svensson, J., Greilert-Norin, N., Bacchus, P., Nilsson, P., Hober,
929		S., Gordon, M., Blom, K., Klingström, J., et al. (2022). Anti-Spike Mucosal IgA Protection

930		against SARS-CoV-2 Omicron Infection. New England Journal of Medicine 387, 1333–
931		1336. https://doi.org/10.1056/NEJMc2209651.
932	25.	Zuo, J., Dowell, A.C., Pearce, H., Verma, K., Long, H.M., Begum, J., Aiano, F., Amin-
933		Chowdhury, Z., Hallis, B., Stapley, L., et al. (2021). Robust SARS-CoV-2-specific T cell
934		immunity is maintained at 6 months following primary infection. Nat Immunol 22, 620-
935		626. https://doi.org/10.1038/s41590-021-00902-8.
936	26.	Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I.,
937		Graichen, L., Moldenhauer, A.S., Winkler, M.S., et al. (2022). The Omicron variant is
938		highly resistant against antibody-mediated neutralization: Implications for control of the
939		COVID-19 pandemic. Cell 185, 447-456.e11. https://doi.org/10.1016/j.cell.2021.12.032.
940	27.	Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M.M.,
941		Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021). Reduced sensitivity of SARS-
942		CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280.
943		https://doi.org/10.1038/s41586-021-03777-9.
944	28.	Loyal, L., Braun, J., Henze, L., Kruse, B., Dingeldey, M., Reimer, U., Kern, F., Schwarz, T.,
945		Mangold, M., Unger, C., et al. (2021). Cross-reactive CD4+ T cells enhance SARS-CoV-2
946		immune responses upon infection and vaccination. Science (1979) 374.
947		https://doi.org/10.1126/science.abh1823.
948	29.	Swadling, L., Diniz, M.O., Schmidt, N.M., Amin, O.E., Chandran, A., Shaw, E., Pade, C.,
949		Gibbons, J.M., Le Bert, N., Tan, A.T., et al. (2022). Pre-existing polymerase-specific T cells
950		expand in abortive seronegative SARS-CoV-2. Nature 601, 110–117.
951		https://doi.org/10.1038/s41586-021-04186-8.
952	30.	Mitchell et al (2024) (under review).
953	31.	Payne, R.P., Longet, S., Austin, J.A., Skelly, D.T., Dejnirattisai, W., Adele, S., Meardon, N.,
954		Faustini, S., Al-Taei, S., Moore, S.C., et al. (2021). Immunogenicity of standard and
955		extended dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699-5714.e11.
956		https://doi.org/https://doi.org/10.1016/j.cell.2021.10.011.
957	32.	Shrotri, M., Fragaszy, E., Nguyen, V., Navaratnam, A.M.D., Geismar, C., Beale, S., Kovar, J.,
958		Byrne, T.E., Fong, W.L.E., Patel, P., et al. (2022). Spike-antibody responses to COVID-19
959		vaccination by demographic and clinical factors in a prospective community cohort study.
960		Nat Commun 13. https://doi.org/10.1038/s41467-022-33550-z.
961	33.	Sano, K., Bhavsar, D., Singh, G., Floda, D., Srivastava, K., Gleason, C., Amoako, A.A., Andre,
962		D., Beach, K.F., Bermudez-Gonzalez, M.C., et al. (2022). SARS-COV-2 vaccination induces
963		mucosal antibody responses in previously infected individuals. Nat Commun 13.
964	24	nπps://doi.org/10.1038/s4146/-022-32389-8.
965	34.	Azzi, L., Dalla Gasperina, D., Veronesi, G., Shallak, M., letto, G., lovino, D., Baj, A.,
966		Gianragna, F., Maurino, V., Focosi, D., et al. (2022). Mucosai immune response in
967	25	BN116202 COVID-19 Vaccine recipients. https://doi.org/10.1016/j.
900	55.	Alu, A., Chen, L., Fuquan, H.L., Han, W.A., and Wei, A. (2022). Intranasal COVID-19
909		vaccines. From bench to bed-NC-ND license (http://creativecommons.org/licenses/by-lic-
970 071	26	Mudd P.A. Minervina A.A. Pogorely, M.V. Turper J.S. Kim W. Kalaidina E
971	50.	Petersen Schmitz A Lei T Haile A et al (2022) SARS-CoV-2 mRNA vaccination
972		elicits a robust and persistent T follicular beloer cell response in humans. Cell 185, 603-
974		613 e15 https://doi.org/10.1016/i.cell.2021.12.026
975	37	Swanson II P A Padilla M Hoyland W Mcglinchey K Fields P A Bibi S Faust S N
976	57.	Mcdermott ΔB Lambe T Pollard ΔL et al (2021) $\Delta TD1222/Ch\Delta dOx1 nCoV-19$
977		vaccination induces a polyfunctional spike protein-specific T H 1 response with a diverse
978		TCR repertoire.
979	38.	Maringer, Y., Nelde, A., Schroeder, S.M., Schuhmacher, J., Hörber, S., Peter, A., Karbach
980		J., Jäger, E., and Walz, J.S. (2022). Durable spike-specific T cell responses after different
981		COVID-19 vaccination regimens are not further enhanced by booster vaccination.

	20	
982	39.	Rivino, L., Kumaran, E.A., Thein, TL., Too, C.T., Chin, V., Gan, H., Hanson, B.J., Wilder-
983		Smith, A., Bertoletti, A., Gascoigne, N.R.J., et al. Virus-specific T lymphocytes home to the
984		skin during natural dengue infection.
985	40.	Kim, T.S., and Shin, E.C. (2019). The activation of bystander CD8+ T cells and their roles in
986		viral infection. Preprint at Springer Nature, https://doi.org/10.1038/s12276-019-0316-1
987		https://doi.org/10.1038/s12276-019-0316-1.
988	41.	Messina, N.L., Zimmermann, P., and Curtis, N. (2019). The impact of vaccines on
989		heterologous adaptive immunity. Preprint at Elsevier B.V.,
990		https://doi.org/10.1016/j.cmi.2019.02.016 https://doi.org/10.1016/j.cmi.2019.02.016.
991	42.	Lee, H.G., Cho, M.Z., and Choi, J.M. (2020). Bystander CD4+ T cells: crossroads between
992		innate and adaptive immunity. Preprint at Springer Nature,
993		https://doi.org/10.1038/s12276-020-00486-7 https://doi.org/10.1038/s12276-020-
994		00486-7.
995	43.	Kim, T.S., and Shin, E.C. (2019). The activation of bystander CD8+ T cells and their roles in
996		viral infection. Preprint at Springer Nature, https://doi.org/10.1038/s12276-019-0316-1
997		https://doi.org/10.1038/s12276-019-0316-1.
998	44.	Di Genova, G., Savelyeva, N., Suchacki, A., Thirdborough, S.M., and Stevenson, F.K.
999		(2010). Bystander stimulation of activated CD4+ T cells of unrelated specificity following a
1000		booster vaccination with tetanus toxoid. Eur J Immunol 40, 976–985.
1001		https://doi.org/10.1002/eji.200940017.
1002	45.	Whiteside, S.K., Snook, J.P., Williams, M.A., and Weis, J.J. (2018). Bystander T Cells: A
1003		Balancing Act of Friends and Foes. Preprint at Elsevier Ltd,
1004		https://doi.org/10.1016/i.it.2018.10.003 https://doi.org/10.1016/i.it.2018.10.003.
1005	46.	Hall, V., Foulkes, S., Insalata, F., Kirwan, P., Saei, A., Atti, A., Wellington, E., Khawam, J.,
1006		Munro, K., Cole, M., et al. (2022). Protection against SARS-CoV-2 after Covid-19
1007		Vaccination and Previous Infection. New England Journal of Medicine 386, 1207–1220.
1008		https://doi.org/10.1056/neimoa2118691.
1009	47.	Levin, E.G., Lustig, Y., Cohen, C., Eluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K.,
1010		Mendelson E. Ziv A. et al. (2021) Waning Immune Humoral Response to BNT162b2
1011		Covid-19 Vaccine over 6 Months, New England Journal of Medicine 385, e84
1012		https://doi.org/10.1056/NFIMoa2114583
1013	48	Pérez-Alós I Armenteros IIA Madsen IR Hansen C.B. Jarlhelt I. Hamm S.B.
1014	101	Heftdal, L.D., Pries-Heie, M.M., Møller, D.L., Fogh, K., et al. (2022). Modeling of waning
1015		immunity after SARS-CoV-2 vaccination and influencing factors. Nat Commun 13, 1614
1016		https://doi.org/10.1038/s41467-022-29225-4
1017	49	Carabelli A M. Peacock T.P. Thorne I.G. Harvey W.T. Hughes I. de Silva T.I.
1018	15.	Peacock S Barclay W S de Silva T Towers G et al (2023) SARS-CoV-2 variant
1010		hiology: immune escane transmission and fitness. Prenrint at Nature Research
1020		https://doi.org/10.1038/s41579-022-00841-7.https://doi.org/10.1038/s41579-022-
1020		00841-7
1021	50	Lustig V. Gonen T. Meltzer I. Gilboa M. Indenhaum V. Cohen C. Amit S. Jaher H.
1022	50.	Doolman B. Asraf K. et al. (2022). Superior immunogenicity and effectiveness of the
1023		third compared to the second BNT162b2 vaccine dose. Nat Immunol 22, 940–946
1024		https://doi.org/10.1038/s/1590-022-01212-3
1025	51	Eang S Dhilling D I White T Saval H Aley D K Bibi S Dold C Euskova M
1020	JT.	Gilbert S.C. Hirsch I. et al. (2021). Correlates of protection against symptomatic and
1027		and the second s
1020		asymptomatic SARS-COV-2 intection. Nat Meu 27, 2052-2040.
1029	ГĴ	IIILUS.//UUI.UIS/IU.IUS0/S4IJJI-UZI-UIJ4U-I.
1030	52.	Gilbert, F.B., Montenon, D.C., McDermolt, A.B., Fong, T., Benkeser, D., Deng, W., Zhou,
1031		n., nouchens, c.K., wardins, K., Jayasharikar, L., et al. (2022). Immune correlates analysis
1032		or the mixina-1273 COVID-19 valcine emicacy clinical trial. Science (1979) 375, 43–50.
1033		nups://doi.org/10.1126/science.abm3425.

1034	53.	Regev-Yochay, G., Lustig, Y., Joseph, G., Gilboa, M., Barda, N., Gens, I., Indenbaum, V.,
1035		Halpern, O., Katz-Likvornik, S., Levin, T., et al. (2023). Correlates of protection against
1036		COVID-19 infection and intensity of symptomatic disease in vaccinated individuals
1037		exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study. Lancet
1038		Microbe 4, e309–e318. https://doi.org/10.1016/S2666-5247(23)00012-5.
1039	54.	Gromowski, G.D., Cincotta, C.M., Mayer, S., King, J., Swafford, I., McCracken, M.K.,
1040		Coleman, D., Enoch, J., Storme, C., Darden, J., et al. (2023). Humoral immune responses
1041		associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US
1042		military population. EBioMedicine <i>94</i> . https://doi.org/10.1016/i.ebiom.2023.104683.
1043	55.	Painter, M.M., Johnston, T.S., Lundgreen, K.A., Santos, J.J.S., Qin, J.S., Goel, R.R.,
1044		Apostolidis, S.A., Mathew, D., Fulmer, B., Williams, J.C., et al. (2023). Prior vaccination
1045		promotes early activation of memory T cells and enhances immune responses during
1046		SARS-CoV-2 breakthrough infection. Nat Immunol 24. 1711–1724.
1047		https://doi.org/10.1038/s41590-023-01613-v.
1048	56.	Neale, J., Ali, M., Kronsteiner, B., Longet, S., Abraham, P., Deeks, A.S., Brown, A., Moore,
1049		S.C., Stafford, L., Dobson, S.L., et al. (2023). CD4+ and CD8+ T cells and antibodies are
1050		associated with protection against Delta vaccine breakthrough infection: a nested case-
1051		control study within the PITCH study, mBio 14, https://doi.org/10.1128/mbio.01212-23
1052	57	Brasu N Elia I Russo V Montarchiesi G Stabile S A De Intinis C Fesi E Gizzi K
1052	57.	Macagno M Montone M et al. (2022) Memory CD8+ T cell diversity and B cell
1054		responses correlate with protection against SARS-CoV-2 following mRNA vaccination Nat
1055		Immunol 23 1445–1456 https://doi.org/10.1038/s41590-022-01313-7
1056	58	Almendro-Vázquez P. Chivite-Lacaba M. Litrero-Rico A. González-Cuadrado C
1050	50.	Laguna-Gova R. Moreno-Batanero M. Sánchez-Paz I. Luczkowiak I. Labiod N
1058		Edgueira M.D. et al. (2022). Cellular and humoral immune responses and breakthrough
1050		infections after three SARS-CoV-2 mRNA vaccine doses. Front Immunol 13
1055		https://doi.org/10.3380/fimmu.2022.981350
1061	50	Goldberg V Mandel M Bar-On V M Bodenbeimer O Freedman I S Ash N Alroy-
1062	55.	Preis S Hunnert A and Milo B (2022) Protection and Waning of Natural and Hybrid
1062		Immunity to SARS-CoV-2 New England Journal of Medicine 386, 2201–2212
1064		https://doi.org/10.1056/neimoa2118946
1065	60	Abu-Raddad I I Chemaitelly H Avoub H H Vassine H M Benslimane F.M. Al
1065	00.	Khatih H A Tang P Hasan M R Covle P Al Kanaani 7 et al (2021) Association of
1067		Prior SARS_CoV_2 Infection With Risk of Breakthrough Infection Following mRNA
1068		Vaccination in Oatar IAMA 326 1930–1939 https://doi.org/10.1001/jama.2021.19623
1069	61	Bowman K A Stein D Shin S Ferbas K G Tohin N H Mann C Fischinger S
1005	01.	Sanhira F.O. Lauffenburger D. Pimoin A.W. et al. (2022) Hybrid Immunity Shifts the
1070		E-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity mRio 13
1071		https://doi.org/10.1128/mbio.01647-22
1072	62	Rodda I B. Morawski P.A. Pruner K.B. Fahning M.L. Howard C.A. Franko N. Logue
1073	02.	L Eggenberger L Stokes C Golez L et al (2022) Imprinted SAPS-CoV-2-specific
1074		memory lymphocytes define hybrid immunity. Cell 185, 1588-1601 e14
1075		https://doi.org/10.1016/i.cell 2022.03.018
1070	63	Carazo S Skowronski D M Brisson M Barkati S Sauvageau C Brousseau N Gilca
1077	03.	P Enford I Talbot D. Quakki M. et al. (2022) Protection against omicron (R 1 1 520)
1078		R. 2 reinfection conferred by primary emicron RA 1 or pro emicron SARS CoV 2 infection
1079		among health care workers with and without mPNA vassination: a test negative case
1000		control study Lancet Infact Dis 22 45-55 https://doi.org/10.1016/S1472
1001		2000/22)00578-2
1002	64	SUSS(22)UUS/0-3. Revnolds C.L. Gibbons, I.M. Pado, C. Lin, K. M. Muñoz Sandoval, D. Dianar, E. Butlar
1084	04.	DK Liu S Otter A D Joy C et al Heterologous infection and vascination change
1004		immunity against SARS CoV 2 variants
1002		initiality against SARS-COV-2 variants.

1086	65.	Walls, A.C., Sprouse, K.R., Bowen, J.F., Joshi, A., Franko, N., Navarro, M.J., Stewart, C.,
1087	00.	Cameroni, E., McCallum, M., Goecker, F.A., et al. (2022). SARS-CoV-2 breakthrough
1088		infections elicit potent, broad, and durable neutralizing antibody responses. Cell 185.
1089		872-880.e3. https://doi.org/10.1016/i.cell.2022.01.011.
1090	66.	Bertoletti, A., Le Bert, N., Qui, M., and Tan, A.T. (2021). SARS-CoV-2-specific T cells in
1091		infection and vaccination. Preprint at Springer Nature. https://doi.org/10.1038/s41423-
1092		021-00743-3 https://doi.org/10.1038/s41423-021-00743-3.
1093	67.	Nguyen, T.H.O., Cohen, C.A., Rowntree, L.C., Bull, M.B., Hachim, A., Kedzierska, K., and
1094	••••	Valkenburg, S.A. (2021). T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and
1095		Against Future Variants. Preprint at Frontiers Media S.A
1096		https://doi.org/10.3389/fmed.2021.793102 https://doi.org/10.3389/fmed.2021.793102.
1097	68.	Lo Tartaro, D., Paolini, A., Mattioli, M., Swatler, J., Neroni, A., Borella, R., Santacroce, E.,
1098		Di Nella, A., Gozzi, L., Busani, S., et al. (2023). Detailed characterization of SARS-CoV-2-
1099		specific T and B cells after infection or heterologous vaccination. Front Immunol 14.
1100		https://doi.org/10.3389/fimmu.2023.1123724.
1101	69.	Kohler, P., Güsewell, S., Seneghini, M., Egger, T., Leal, O., Brucher, A., Lemmenmeier, E.,
1102		Möller, J.C., Rieder, P., Ruetti, M., et al. (2021). Impact of baseline SARS-CoV-2 antibody
1103		status on syndromic surveillance and the risk of subsequent COVID-19—a prospective
1104		multicenter cohort study. BMC Med 19. https://doi.org/10.1186/s12916-021-02144-9.
1105	70.	Follmann, D., Janes, H.E., Buhule, O.D., Zhou, H., Girard, B., Marks, K., Kotloff, K.,
1106		Desiardins, M., Corey, L., Neuzil, K.M., et al. (2022). Antinucleocapsid Antibodies After
1107		SARS-CoV-2 Infection in the Blinded Phase of the Randomized. Placebo-Controlled mRNA-
1108		1273 COVID-19 Vaccine Efficacy Clinical Trial. Ann Intern Med 175. 1258–1265.
1109		https://doi.org/10.7326/M22-1300.
1110	71.	Allen, N., Brady, M., Carrion Martin, A.I., Domegan, L., Walsh, C., Doherty, L., Riain, U.N.,
1111		Bergin, C., Fleming, C., and Conlon, N. (2021). Serological markers of SARS-CoV-2
1112		infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural
1113		infection in vaccinated individuals. Journal of Infection 83, e9–e10.
1114		https://doi.org/https://doi.org/10.1016/j.jinf.2021.08.012.
1115	72.	Williams, D.M., Hornsby, H.R., Shehata, O.M., Brown, R., Gallis, M., Meardon, N.,
1116		Newman, T.A.H., Plowright, M., Zafred, D., Shun-Shion, A.S.M., et al. (2023). Establishing
1117		SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via
1118		high-content microscopy. iScience 26. https://doi.org/10.1016/j.isci.2023.107056.
1119	73.	Northstone, K., Ben Shlomo, Y., Teyhan, A., Hill, A., Groom, A., Mumme, M., Timpson, N.,
1120		and Golding, J. (2023). The Avon Longitudinal Study of Parents and children ALSPAC GO
1121		Partners: A cohort profile. Wellcome Open Res 8, 37.
1122		https://doi.org/10.12688/wellcomeopenres.18782.1.
1123	74.	Fraser, A., Macdonald-wallis, C., Tilling, K., Boyd, A., Golding, J., Davey smith, G.,
1124		Henderson, J., Macleod, J., Molloy, L., Ness, A., et al. (2013). Cohort profile: The avon
1125		longitudinal study of parents and children: ALSPAC mothers cohort. Int J Epidemiol 42,
1126		97–110. https://doi.org/10.1093/ije/dys066.
1127	75.	Boyd, A., Golding, J., Macleod, J., Lawlor, D.A., Fraser, A., Henderson, J., Molloy, L., Ness,
1128		A., Ring, S., and Smith, G.D. (2013). Cohort profile: The 'Children of the 90s'-The index
1129		offspring of the avon longitudinal study of parents and children. Int J Epidemiol 42, 111–
1130		127. https://doi.org/10.1093/ije/dys064.
1131	76.	Northstone, K., Lewcock, M., Groom, A., Boyd, A., Macleod, J., Timpson, N., and Wells, N.
1132		(2019). The Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the
1133		enrolled sample of index children in 2019. Wellcome Open Res 4.
1134		https://doi.org/10.12688/wellcomeopenres.15132.1.
1135	77.	ALSPAC data dictionary http://www.bristol.ac.uk/alspac/researchers/our-data/.
1136	78.	Northstone, K., Smith, D., Bowring, C., Hill, A., Hobbs, R., Wells, N., and Timpson, N.J.
1137		(2021). The Avon Longitudinal Study of Parents and Children - A resource for COVID-19

1138		research: Home-based antibody testing results, October 2020. Wellcome Open Res 6.
1139		https://doi.org/10.12688/wellcomeopenres.16616.1.
1140	79.	Halliday, A., Long, A.E., Baum, H.E., Thomas, A.C., Shelley, K.L., Oliver, E., Gupta, K.,
1141		Francis, O., Williamson, M.K., Di Bartolo, N., et al. (2022). Development and evaluation of
1142		low-volume tests to detect and characterize antibodies to SARS-CoV-2. Front Immunol
1143		13. https://doi.org/10.3389/fimmu.2022.968317.
1144	80.	Thomas, A.C., Oliver, E., Baum, H.E., Gupta, K., Shelley, K.L., Long, A.E., Jones, H.E., Smith,
1145		J., Hitchings, B., di Bartolo, N., et al. (2023). Evaluation and deployment of isotype-
1146		specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children
1147		and adults. Communications Medicine 3, 37. https://doi.org/10.1038/s43856-023-00264-
1148		2.
1149	81.	Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., and Conde, J.G. (2009).
1150		Research electronic data capture (REDCap)-A metadata-driven methodology and
1151		workflow process for providing translational research informatics support. J Biomed
1152		Inform 42, 377–381. https://doi.org/10.1016/j.jbi.2008.08.010.
1153		



Figure 1: Study design.





73

Ċ

107

control

107

N ACK

control

73

107

0

control

80 ●

act of the

0

0

control

8

78 ©

0

Figure 2: Antibody and T-cell responses to COVID-19 vaccination in SARS-CoV-2 naïve and previously infected individuals.





2

3 4

5

CD107a

IFN-γ

IL-2

MIP1B

TNF-α

Figure 3: SARS-CoV-2-specific CD4+ and CD8 + T-cell responses in previously infected individuals.



Figure 4: Association between immune responses to prior SARS-CoV-2 infection and COVID-19 vaccination and susceptibility to SARS-CoV-2 breakthrough infection.

	Cases (N=199)	Controls (N=176)
Sex		
Female / male (n)	142 / 57	80 / 96
Age		
G0 / G1 (n)	77 / 122	79 / 98
Mean age (years)	39	42
Median age (years)	29	29
Age unknown (n)	22	0
Ethnicity		
Asian/Asian British (n)	< 5	< 5
Black/African/ Caribbean/ Black British (n)	< 5	< 5
Arab or other ethnic group (n)	< 5	< 5
Mixed/multiple ethnic groups (n)	< 5	< 5
White (n)	≥ 166	≥144
Ethnicity data not available (n)	8	9

Table S2: Statistical comparison of monofunctional SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells in previously infected individuals.

		Individual P Value /	Individual P Value /	
Cytokines	Protein	Monofunctional CD4 ⁺ T-cells	Monofunctional CD8 ⁺ T-cells	
	S1	0.0966	<0.0001	
	S2	0.1297	<0.0001	
MIP1β vs IL2	М	>0.9999	<0.0001	
	N	0.0146	<0.0001	
	NSP3B	0.0658	<0.0001	
	S1	0.0074	<0.0001	
	S2	0.5881	<0.0001	
MIP1β vs CD107a	M	<0.0001	<0.0001	
	N	0.08	<0.0001	
	NSP3B	0.9148	<0.0001	
	S1	0.0227	<0.0001	
	S2	0.0034	<0.0001	
MIP1B VS IFNY	M	0.0003	<0.0001	
	N	0.0134	<0.0001	
	NSP3B	0.208	<0.0001	
	S1	<0.0001	0.007	
	S2	<0.0001	0.002	
MIPTO VS TNFa	M	<0.0001	<0.0001	
	N	<0.0001	<0.0001	
	NSP3B	<0.0001	0.0011	
	S1	0.3092	0.0492	
U.O. OD407	52	0.0397	0.6678	
IL2 VS CD107a	IVI N	<0.0001	0.0015	
		0.4888	0.3073	
	NOF 3D Q1	<0.0001	0.3519	
	51	<0.0001	0.1972	
	32 M	<0.0001	0.0309	
ILZ VS IFINY	N	<0.0001	0.0295	
	NSD3B	0.0019	0.0581	
	S1	<0.001	<0.0001	
	S2	<0.0001	<0.0001	
II 2 vs TNEa	M	<0.0001	0.002	
	N	<0.0001	0.0002	
	NSP3B	<0.0001	<0.0001	
	S1	<0.0001	0.0011	
	S2	0.0171	0.0837	
CD107a vs IFNγ	М	>0.9999	0.3141	
	Ν	<0.0001	0.0029	
	NSP3B	0.1719	0.4961	
	S1	<0.0001	<0.0001	
	S2	<0.0001	<0.0001	
CD107a vs TNF α	Μ	0.1842	0.9218	
	Ν	<0.0001	<0.0001	
	NSP3B	<0.0001	<0.0001	
	S1	<0.0001	0.005	
	S2	<0.0001	0.0113	
IFNγ vs TNFα	Μ	0.0566	0.3636	
	Ν	0.0001	0.1086	
	NSP3B	0.002	0.0004	

Table S3: Characteristics of the infection susceptibility groups.

	Са	ses	Controls	
	Breakthrough infection	No breakthrough infection	Breakthrough infection	No breakthrough infection
Total (n)	8	18	14	19
Proportion of group reinfected (%)	30.8%	/	42.4%	/
Triple vaccinated before infection (%)	75.0%	/	78.6%	/
COVID-19 vaccines dose 1&2 = mRNA (%)	75.0%	44.4%	14.3%	21.1%
Days since vaccine dose 2 (median; IQR)	50 (31-71)	40 (29-54)	50 (42-59)	41 (26-49)
Female (%)	100%	72.2%	71.4%	78.9%
G0 generation (%)	37.5%	83.3%	100%	100%
Reported having a weakened immune system	0.0%	5.6%	0.0%	0.0%
Limited contacts before meeting friends / relatives	50.0%	22.2%	50.0%	36.8%
Shopped online rather than visiting shops	20.0%	11.1%	35.7%	31.6%



Supplementary Figure 1: Participants inclusion flowchart.



Supplementary Figure 2: Anti-N pan Ig levels in control participants before and after vaccine dose 1.



Supplementary Figure 3: Correlation between SARS-CoV-2 Spike-specific serum IgG and pseduoneutralising antibody levels.



Supplementary Figure 4: Antibody and T cell responses by COVID-19 vaccination type.

А



0 doses

1 dose

2 dose



Supplementary Figure 5: Magnitude of T-cell response following COVID-19 vaccination

Α



Supplementary Figure 6: Gating-strategy for the identification of SARS-CoV-2-reactive cytokine producing CD4⁺ and CD8⁺ T-cells



Supplementary Figure 7: Frequency of monofunctional SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells in previously infected individuals.



Supplementary Figure 8: Frequency of polyfunctional SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells in previously infected individuals.



Supplementary Figure 9: Comparison of post-vaccination dose 2 antibody and T-cell levels in participants with and without a reported SARS-CoV-2 breakthrough infection.



Supplementary Figure 10: Breakthrough infection susceptibility Youden's index threshold setting



Supplementary Figure 11: Performance of combined thresholds for breakthrough infection susceptibility.